EGFR and lung adenocarcinoma: demonstrated that in epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (LUAD), succinylation of ACAT1 by SIRT5 activates the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway, which suppresses chemokine secretion essential for CD8+ T cell recruitment (161).